我猜测现在的重症患者没几个敢参加双盲的如果被分到安慰剂那组，死亡率还是挺高的
我相信数据是真实的
换了个积极的说法而已
但是3期报告这样不是科学报告可以接受的
new release 没问题，随便怎么解释。
Gilead的三期是双盲设计的
https://www.businessinsider.sg/coronavirus-treatment-data-on-gilead-remdesivir-who-2020-4?r=US&IR=T
The trial ended up including 237 participants, with 158 receiving remdesivir and 79 receiving a placebo. It was designed to enroll 453 people.
The summary said that about 14% of those taking remdesivir had died after a month, compared with about 13% of those in the placebo group,
但是3期报告这样不是科学报告可以接受的
new release 没问题，随便怎么解释。
Gilead的三期是双盲设计的
https://www.businessinsider.sg/coronavirus-treatment-data-on-gilead-remdesivir-who-2020-4?r=US&IR=T
The trial ended up including 237 participants, with 158 receiving remdesivir and 79 receiving a placebo. It was designed to enroll 453 people.
The summary said that about 14% of those taking remdesivir had died after a month, compared with about 13% of those in the placebo group,
Huasing Association 1999 - 2013